Alton C. Morgan

Monoclonal antibody therapy of human cancer

1. Monoclonal Antibody Therapy of Cancer: Parameters Which Affect the Efficacy of Immunotoxins.- 2. Design and Development of Drug-Monoclonal Antibody 791T/36 Conjugate for Cancer Therapy.- 3. Monoclonal Antibodies Directed Towards Growth-Related Receptors on Human Tumors.- 4. Monoclonal Antibody Therapy for Patients with Leukemia and Lymphoma.- 5. Monoclonal Antibody Therapy of Solid Tumors.- 6. Human Immune Responses to Murine Monoclonal Antibodies.- 7. Radiolabeled Monoclonal Antibodies for Imaging and Therapy.

Immunoconjugates of a Protein Synthesis-Inhibiting Drug

Trichothecenes are a class of mycotoxins that are potent inhibitors of protein synthesis (Alder et al., 1984). In fact, they are among the most active cytotoxic agents known when tested against cultured tumor cells. The manifestations of their toxicities against a living host are quite varied, ranging from necrotizing dermatitis to death.

Monoclonal Antibody Therapy of Cancer: Parameters Which Affect the Afficacy of Immunotoxins

The major problems with the current modalities of cancer therapy are the lack of tumor specificity and the low therapeutic/toxic ratio of anticancer drugs and radiation therapy. A major advance in the treatment of cancer could be heralded by the development of a class of agents that have a greater degree of tumor specificity. The technique of hybridization of an immortal myeloma cell line with an antibody-producing B cell, developed by Kohler and Milstein (1), provides a technique by which monoclonal antibodies with considerable tumor specificity could be produced in unlimited quantities.